CD8A and neoplasm: Consistent with these studies, Hannah and colleagues demonstrated that STING agonists (10 μg of cGAMP or 25 μg ofRR-CDA) treatment combined with VEGFR2 blockade (DC101) enhanced the infiltration of CD8+ T cells in the tumor microenvironment and induces complete tumor regression [59], this exciting result suggests that simultaneously targeting STING and VEGF signaling represents a promising strategy for cancer therapy.